The United States Patent and Trademark Office (USPTO) has issued patent US12583835B2, detailing a novel crystal form of a nitroxoline prodrug, a pharmaceutical composition incorporating this form, and methods for its preparation and application. The patent specifically describes two crystal forms, A and B, characterized by distinct X-ray powder diffraction patterns. These forms are presented as advantageous over existing nitroxoline due to reduced staining, lower equipment requirements for industrial production, and enhanced stability for quality control and drug efficacy.

This patent grant signifies the USPTO's recognition of intellectual property rights for Jiangsu Yahong Meditech Co., Ltd. regarding this specific chemical compound and its pharmaceutical applications. While this is a patent grant and not a regulatory rule imposing direct compliance obligations on other entities, it establishes exclusive rights for the assignee. Companies operating in the pharmaceutical sector, particularly those involved in the development or manufacturing of nitroxoline-based drugs or similar prodrugs, should be aware of this patent to avoid potential infringement. No immediate compliance actions are required for entities not involved with this specific patented technology, but it highlights the importance of IP due diligence in drug development.